

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 July 2022 (14.07.2022)



(10) International Publication Number
WO 2022/150605 A1

(51) International Patent Classification:

A61K 39/35 (2006.01) *A61P 37/08* (2006.01)
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)

(21) International Application Number:

PCT/US2022/011643

(22) International Filing Date:

07 January 2022 (07.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/135,238 08 January 2021 (08.01.2021) US
21315241.6 10 November 2021 (10.11.2021) EP

(71) Applicants: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **SANOFI BIOTECHNOLOGY** [FR/FR]; 54 rue La Boetie, 75008 Paris, Paris (FR).

(72) Inventors: **ORENGO, Jamie M.**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **RADIN, Allen**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **RUDDY, Marcella**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **STAUDINGER, Heribert**; c/o Sanofi, 55 Corporate Drive, Bridgewater, New Jersey 08807 (US). **WANG, Qiufan**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **SMITH, Ryan C.** et al.; P.O. Box 2903, Minneapolis, Minnesota 55402-0903 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

WO 2022/150605 A1

(54) Title: METHODS FOR TREATING PEANUT ALLERGY AND ENHANCING PEANUT ALLERGEN-SPECIFIC IMMUNOTHERAPY BY ADMINISTERING AN IL-4R ANTAGONIST

(57) Abstract: Methods for enhancing the efficacy, safety, and/or tolerability of a peanut allergen-specific immunotherapy regimen in a subject having a peanut allergy, comprising administering an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen-binding fragment thereof in combination with the immunotherapy, are provided.